Table 1 Baseline characteristics of patients (n=42)

From: A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group

 

Median

64

 

Age (years)

Range

31–74

(%)

Recurrent

 

27

(64)

Advanced

 

15

(36)

 Stage III

 

8

 

 Stage IV

 

7

 

ECOG PS

0

28

(67)

 

1

13

(31)

 

2

1

(2)

Grading

1

5

(12)

 

2

20

(48)

 

3

15

(36)

 

NA

2

(4)

Histologic type

Endometrioid

35

(83)

 

Squamous

1

(2)

 

Serous

4

(10)

 

Clear cell

2

(5)

  1. NA=not available; PS=performance status.
Back to article page